Year-end Sale % OFF 
Abstract
Fanconi anemia (FA) is a disease that could be accompanied by multiple abnormalities, such as growth retardation, bone marrow abnormalities, and cancer susceptibility. Among the FA patients, head and neck squamous cell cancer (HNSCC) is the most observed solid cancer. The life expectancy of patients with FA has increased with recent medical advances. Furthermore, HNSCC is diagnosed in 3% of FA patients, and half of these patients die because of their HNSCC. The median age of HNSCC patients with FA is 31, and according to the literature HNSCC incidence of FA, patients is more than 700-fold of the normal population. Here, we reported the treatment details and challenges we faced during hypopharyngeal cancer treatment in a FA patient.
Highlights
Fanconi anemia (FA) is a genetic bone marrow failure syndrome characterized by pancytopenia
FA patients are strongly prone to head and neck squamous cell cancer (HNSCC) development; they have an earlier onset for HNSCC [2]
In a study by Gluckman et al, five patients diagnosed with Fanconi anemia underwent hematopoietic stem cell transplantation after a preparation regimen with cyclophosphamide, and severe cyclophosphamide-related toxicity was observed in all of them
Summary
Fanconi anemia (FA) is a genetic bone marrow failure syndrome characterized by pancytopenia. To confirm the diagnosis of FA, we communicated with the related university hospital for the records of the patients 20 years ago They approved the diagnosis of FA with some peripheric blood sample studies without giving details. The patient's first notable characteristic was growth retardation manifested by short stature, microcephaly, and microphthalmia Afterward, she had swallowing difficulty for the last two years and had lost around 10 kg in the last six months. The remaining maintenance dosage was scheduled as 250 mg/m2 but could not be administered due to a sudden drop in blood count (white blood count to 0.48x103cells/uL) after four days of initial cetuximab and 10 days of RT Her treatment was terminated due to progressive cytopenia (Table 1), after receiving 21.2 Gy in 10 days for primary lesion.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
